Although the 400-person study was too small to really compare clinical outcomes, Tanigaki said a count of major adverse ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

With all of the healthcare funding cuts currently going on in Washington, there is one health service that has survived ...

At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage repair (DDR)-deficient localized prostate cancer offered new insights -- but ...

The outrage over prescription drug pricing in the U.S. is justified. Americans routinely pay two to three times more for ...

By "making T cells happier," the widely used selective serotonin reuptake inhibitor (SSRI) class of antidepressants enhanced ...

While rates of bile duct injury were similar with robotic-assisted cholecystectomy and laparoscopic cholecystectomy among ...

A new FDA policy will make COVID boosters available for high-risk groups, but harder to get for many Americans.

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes ...